tirzepatide thyroid Tirzepatide and Thyroid Nodules: Safety

Semaglutide is a relatively novel glucagon-like peptide-1 (GLP-1) receptor agonist that is currently approved to treat diabetes and promote weight loss in overweight and obese individuals

Seven more are expected in 2026

All GLP-1/GIP receptor agonist medications, including Zepbound, carry an FDA boxed warning related to thyroid tumor risk observed in animal studies

This is often described as a sense of early fullness, mild queasiness, or reduced interest in food rather than severe nausea

A temporary split dosing approach during the transition period, returning to weekly dosing once adapted, can ease this adjustment